News, Events, Publications and Presentations
14th May 2025
Yaqrit strengthens funding and regulatory capability ahead of clinical trials with board and senior management team appointments
7th May 2025
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
7th May 2025
EASL 2025 YAQ005 + YAQ007: Transcriptomic and metabolic insights into hyperammonemia
7th May 2025
EASL 2025 YAQ005: Toll-like receptor 4 inhibition restores cytochrome C oxidase
7th May 2025
EASL 2025: YAQ007 Randomized, open-label, phase 2a comparator study
7th May 2025
EASL 2025 : YAQ001 positively impacts gut microbiome composition
21st Mar 2025
Yaqrit secures NIHR grant for pivotal trials of its liver support device, DIALIVE, for patients with liver failure
21st Feb 2025
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
